<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03152084</url>
  </required_header>
  <id_info>
    <org_study_id>D1690C00049</org_study_id>
    <secondary_id>2016-002961-79</secondary_id>
    <nct_id>NCT03152084</nct_id>
  </id_info>
  <brief_title>The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.</brief_title>
  <acronym>DAPASALT</acronym>
  <official_title>DAPASALT: An Open Label, Phase IV, Mechanistic, Three-Arm Study to Evaluate the Natriuretic Effect of 2-Week Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Either Preserved or Impaired Renal Function and Non-Diabetics With Impaired Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate how dapagliflozin mechanism of action is impacted by&#xD;
      Type 2 Diabetes Mellitus status and kidney function&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor recruitment.&#xD;
  </why_stopped>
  <start_date type="Actual">July 12, 2017</start_date>
  <completion_date type="Actual">March 20, 2020</completion_date>
  <primary_completion_date type="Actual">March 20, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 24-hour Sodium Excretion From Baseline to Start of Treatment</measure>
    <time_frame>From baseline (Day -3 to Day -1) to start of treatment (Day 2 to Day 4)</time_frame>
    <description>Change in 24-hour sodium excretion during dapagliflozin treatment between baseline and average of Days 2 to 4 within each study group in patients with T2DM with preserved kidney function and in non-diabetics with impaired kidney function was assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 24-hour Sodium Excretion From Baseline to End of Treatment and From End of Treatment to Follow-up</measure>
    <time_frame>From baseline (Day -3 to Day -1) to end of treatment (Day 12 to 14); and from end of treatment (Day 12 to 14) to follow-up (Day 15 to 17)</time_frame>
    <description>Average change in 24-hour sodium excretion from average baseline values to average end of treatment values (Day 12 to 14); and from average end of treatment values (Day 12 to 14) to average values during follow-up (Day 15 to 17).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24-hour Glucose Excretion From Baseline to Start of Treatment</measure>
    <time_frame>From baseline (Day -3 to Day -1) to start of treatment (Day 2 to 4)</time_frame>
    <description>Average change in 24-hour glucose excretion from average baseline values to average start of treatment values (Day 2 to 4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24-hour Glucose Excretion From Baseline to End of Treatment</measure>
    <time_frame>From baseline (Day -3 to Day -1) to end of treatment (Day 12 to 14)</time_frame>
    <description>Average change in 24-hour glucose excretion from average baseline values to average end of treatment values (Day 12 to 14)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24-hour Glucose Excretion From End of Treatment to Follow-up</measure>
    <time_frame>From end of treatment (Day 12 to 14) to follow-up (Day 15 to 17)</time_frame>
    <description>Average change in 24-hour glucose excretion from average end of treatment values (Day 12 to 14) to average values during follow-up (Day 15 to 17).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean 24-hour Systolic Blood Pressure From Baseline to Start of Treatment</measure>
    <time_frame>From baseline (Day -1) to start of treatment (Day 4)</time_frame>
    <description>Change in mean 24-hour systolic blood pressure from baseline to start of treatment (Day 4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean 24-hour Systolic Blood Pressure From Baseline to End of Treatment</measure>
    <time_frame>From baseline (Day -1) to end of treatment (Day 13)</time_frame>
    <description>Change in mean 24-hour systolic blood pressure from baseline to end of treatment (Day 13).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean 24-hour Systolic Blood Pressure From End of Treatment to End of Follow-up</measure>
    <time_frame>From end of treatment (Day 13) to end of follow-up (Day 18)</time_frame>
    <description>Change in mean 24-hour systolic blood pressure from end of treatment (Day 13) to end of follow-up (Day 18).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Volume From Baseline to Start of Treatment</measure>
    <time_frame>From baseline (Day 1) to start of treatment (Day 4)</time_frame>
    <description>Change in plasma volume from baseline to start of treatment (Day 4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Volume From Baseline to End of Treatment</measure>
    <time_frame>From baseline (Day 1) to end of treatment (Day 14)</time_frame>
    <description>Change in plasma volume from baseline to end of treatment (Day 14).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Plasma Volume From End of Treatment to End of Follow-up</measure>
    <time_frame>From end of treatment (Day 14) to end of follow-up (Day 18)</time_frame>
    <description>Change in plasma volume from end of treatment (Day 14) to end of follow-up (Day 18).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Extracellular Volume From Baseline to Start of Treatment</measure>
    <time_frame>From baseline (Day 1) to start of treatment (Day 4)</time_frame>
    <description>Change in extracellular volume from baseline to start of treatment (Day 4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Extracellular Volume From Baseline to End of Treatment</measure>
    <time_frame>From baseline (Day 1) to end of treatment (Day 14)</time_frame>
    <description>Change in extracellular volume from baseline to end of treatment (Day 14).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Extracellular Volume From End of Treatment to End of Follow-up</measure>
    <time_frame>From end of treatment (Day 14) to end of follow-up (Day 18)</time_frame>
    <description>Change in extracellular volume from end of treatment (Day 14) to end of follow-up (Day 18).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24-hour Urine Albumin:Creatinine Ratio (UACR)</measure>
    <time_frame>From baseline (Day -3 to Day -1) to start of treatment (Day 4); and from baseline (Day -3 to Day-1) to end of treatment (Day 12 to 14)</time_frame>
    <description>Average change in mean 24-hour urine albumin:creatinine ratio (UACR) from average baseline to Day 4; and from average baseline values to average end of treatment values (Day 12 to 14).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Dapagliflozin on Day 4 and Day 14</measure>
    <time_frame>At pre-dose (Day 4) and at pre-dose, 1h, 2h, 4h post-dose (Day 14)</time_frame>
    <description>Dapagliflozin plasma concentration on Day 4 (pre-dose) and Day 14 (pre-dose, 1h, 2h, 4h post-dose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With AEs and SAEs</measure>
    <time_frame>From Day 1 until Day 18 (Follow-up)</time_frame>
    <description>An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. SAE is an AE that results in any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, or is a significant medical event.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Kidney Function Tests</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T2DM subjects with an eGFR (CKD-EPI) between ≥25 and ≤50 mL/min/1.73m2 at the Screening Visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T2DM subjects with an eGFR (CKD-EPI) between &gt;90 and ≤130 mL/min/1.73m2 for patients aged 59 or younger, between &gt;85 and ≤130 mL/min/1.73m2 for patients aged 60 to 69, and between &gt;75 and ≤130 mL/min/1.73m2 for patients aged 70 or older at the Screening Visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-diabetic subjects with an eGFR (CKD-EPI) between ≥25 and ≤50 mL/min/1.73m2 at the Screening Visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>The study consists of a 2-week, open label, dapagliflozin (10mg) treatment period.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of signed and dated, written informed consent prior to any study specific&#xD;
             procedures&#xD;
&#xD;
          -  Female and/or male aged between 18 years and ≤80 years&#xD;
&#xD;
          -  In the diabetic arms - a diagnosis of T2DM with HbA1c ≥6.5% (≥48 mmol/mol) and &lt;10%&#xD;
             (&lt;86 mmol/mol); and eGFR (CKD-EPI) between ≥25 and ≤50 mL/min/1.73m2 or between &gt;90&#xD;
             and ≤130 mL/min/1.73m2 for patients aged 59 years or younger, between &gt;85 and ≤130&#xD;
             mL/min/1.73m2 for patients aged 60 to 69 years, and between &gt;75 and ≤130 mL/min/1.73m2&#xD;
             for patients aged 70 years or older at the Screening Visit (Visit 1)&#xD;
&#xD;
          -  In the non-diabetic arm, HbA1c &lt;6.5% (&lt;48 mmol/mol) and an eGFR (CKD-EPI) between ≥25&#xD;
             and ≤50 mL/min/1.73m2 at the Screening Visit (Visit 1)&#xD;
&#xD;
          -  Patient specific optimal antihypertensive dose of an angiotensin receptor blocker at&#xD;
             least 6 weeks before study treatment&#xD;
&#xD;
          -  In the diabetic arm (Group 2) an appropriate stable dose of metformin, or&#xD;
             sulphonylurea, or metformin+sulphonylurea as anti-diabetic therapy for the last 12&#xD;
             weeks before study treatment&#xD;
&#xD;
          -  Stable urinary sodium excretion on 2 successive 24-hr urinary sodium excretion&#xD;
             measurements.&#xD;
&#xD;
          -  In the diabetic arm with impaired renal function (Group 1), a stable insulin dosing&#xD;
             (intermediate, long-acting, premixed insulin, basal bolus insulin) for the last 12&#xD;
             weeks prior to Visit 4 (Day 1), as judged by the Investigator. Metformin or&#xD;
             sulphonylurea, or metformin+sulphonylurea together with insulin would be accepted, but&#xD;
             is not mandatory. If used, stable dose of metformin or sulphonylurea, or&#xD;
             metformin+sulphonylurea as anti-diabetic therapy for the last 12 weeks prior to Visit&#xD;
             4 (Day 1) is required.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Type 1 Diabetes Mellitus&#xD;
&#xD;
          -  Any of the following cardiovascular/vascular diseases within 3 months prior to signing&#xD;
             the consent; myocardial infarction, cardiac surgery or revascularization, unstable&#xD;
             angina, unstable heart failure, heart failure NYHA Class IV, transient ischemic attack&#xD;
             or significant cerebrovascular disease, unstable or previously undiagnosed arrhythmia&#xD;
&#xD;
          -  Symptoms/complaints suggestive of established neurogenic bladder and/or incomplete&#xD;
             bladder emptying&#xD;
&#xD;
          -  History of bladder cancer, diagnosis of polycystic kidney disease, history or current&#xD;
             lupus nephritis or unstable or rapidly progressing renal disease&#xD;
&#xD;
          -  UACR &gt;1000 mg/g at screening&#xD;
&#xD;
          -  Current/chronic use of the following medications: any anti-diabetic medication with&#xD;
             the exception of metformin, sulphonylurea, angiotensin converting enzyme inhibitors,&#xD;
             insulin (insulin only allowed in Group 1), oral glucocorticoids, non-steroidal&#xD;
             anti-inflammatory drugs, immune suppressants, chemotherapeutics, antipsychotics,&#xD;
             tricyclic antidepressants and monoamine oxidase inhibitors&#xD;
&#xD;
          -  Receiving immunosuppressive or other immunotherapy for primary or secondary renal&#xD;
             disease within 6 months prior to screening&#xD;
&#xD;
          -  Current treatment or treatment within the last 2 weeks prior to screening with&#xD;
             diuretics including loop diuretics, thiazides, and mineralocorticoid antagonists&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Almelo</city>
        <zip>7609 PP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Örebro</city>
        <zip>70185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D1690C00049&amp;amp;attachmentIdentifier=be370583-b4a1-4b70-beb9-36494cdc972e&amp;amp;fileName=D1690C00049_Redacted_CSP.pdf&amp;amp;versionIdentifier=</url>
    <description>Redacted CSP</description>
  </link>
  <link>
    <url>https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;amp;parentIdentifier=D1690C00049&amp;amp;attachmentIdentifier=c44b2c01-34f0-4182-ab6f-d195ab6b4d61&amp;amp;fileName=D1690C00049_Redacted_SAP.pdf&amp;amp;versionIdentifier=</url>
    <description>Redacted SAP</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 18, 2017</study_first_submitted>
  <study_first_submitted_qc>May 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <results_first_submitted>March 17, 2021</results_first_submitted>
  <results_first_submitted_qc>May 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 28, 2021</results_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment:&#xD;
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 10, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT03152084/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT03152084/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted between 12-Jul-2017 and 20-Mar-2020. Patients who met all the inclusion and none of the exclusion criteria were enrolled in the study.</recruitment_details>
      <pre_assignment_details>All study assessments were performed as per the schedule of assessment. No patients in Group 1 were enrolled into the Run-in set due to failure to meet inclusion exclusion criteria, screen failure, or other reasons. Due to unsatisfactory recruitment rate, it was decided that no more Group 1 patients would be enrolled in the study. Group 1 included type 2 diabetes mellitus (T2DM) patients with impaired kidney function and were to receive oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 2</title>
          <description>Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
        </group>
        <group group_id="P2">
          <title>Group 3</title>
          <description>Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Set: All patients who received at least one dose of study drug and had data from at least one post-dose safety assessment available were included in the safety set.</population>
      <group_list>
        <group group_id="B1">
          <title>Group 2</title>
          <description>Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
        </group>
        <group group_id="B2">
          <title>Group 3</title>
          <description>Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 80 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=80 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in 24-hour Sodium Excretion From Baseline to Start of Treatment</title>
        <description>Change in 24-hour sodium excretion during dapagliflozin treatment between baseline and average of Days 2 to 4 within each study group in patients with T2DM with preserved kidney function and in non-diabetics with impaired kidney function was assessed.</description>
        <time_frame>From baseline (Day -3 to Day -1) to start of treatment (Day 2 to Day 4)</time_frame>
        <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. It excluded primary efficacy variable data which may have been affected by protocol deviations as determined by medical monitor or agreed by study team. For Group 3, early termination of the study resulted in 6 evaluable patients. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2</title>
            <description>Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
          <group group_id="O2">
            <title>Group 3</title>
            <description>Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 24-hour Sodium Excretion From Baseline to Start of Treatment</title>
          <description>Change in 24-hour sodium excretion during dapagliflozin treatment between baseline and average of Days 2 to 4 within each study group in patients with T2DM with preserved kidney function and in non-diabetics with impaired kidney function was assessed.</description>
          <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. It excluded primary efficacy variable data which may have been affected by protocol deviations as determined by medical monitor or agreed by study team. For Group 3, early termination of the study resulted in 6 evaluable patients. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented.</population>
          <units>mmol/24 hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.33" lower_limit="-53.667" upper_limit="44.000"/>
                    <measurement group_id="O2" value="-27.67" lower_limit="-69.334" upper_limit="13.334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Within-group change</non_inferiority_desc>
            <p_value>0.4462</p_value>
            <p_value_desc>Start of treatment vs baseline</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least square mean</param_type>
            <param_value>-5.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.542</ci_lower_limit>
            <ci_upper_limit>9.120</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 24-hour Sodium Excretion From Baseline to End of Treatment and From End of Treatment to Follow-up</title>
        <description>Average change in 24-hour sodium excretion from average baseline values to average end of treatment values (Day 12 to 14); and from average end of treatment values (Day 12 to 14) to average values during follow-up (Day 15 to 17).</description>
        <time_frame>From baseline (Day -3 to Day -1) to end of treatment (Day 12 to 14); and from end of treatment (Day 12 to 14) to follow-up (Day 15 to 17)</time_frame>
        <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. It excluded primary efficacy variable data which may have been affected by protocol deviations as determined by medical monitor or agreed by study team. For Group 3, early termination of the study resulted in 6 evaluable patients. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2</title>
            <description>Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
          <group group_id="O2">
            <title>Group 3</title>
            <description>Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 24-hour Sodium Excretion From Baseline to End of Treatment and From End of Treatment to Follow-up</title>
          <description>Average change in 24-hour sodium excretion from average baseline values to average end of treatment values (Day 12 to 14); and from average end of treatment values (Day 12 to 14) to average values during follow-up (Day 15 to 17).</description>
          <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. It excluded primary efficacy variable data which may have been affected by protocol deviations as determined by medical monitor or agreed by study team. For Group 3, early termination of the study resulted in 6 evaluable patients. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented.</population>
          <units>mmol/24 hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>End of treatment vs baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67" lower_limit="-64.000" upper_limit="143.167"/>
                    <measurement group_id="O2" value="-23.83" lower_limit="-107.000" upper_limit="0.667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up vs end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" lower_limit="-135.334" upper_limit="25.000"/>
                    <measurement group_id="O2" value="6.17" lower_limit="-70.333" upper_limit="20.333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Within-group change</non_inferiority_desc>
            <p_value>0.7842</p_value>
            <p_value_desc>End of treatment vs baseline</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least square mean</param_type>
            <param_value>3.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.817</ci_lower_limit>
            <ci_upper_limit>32.195</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Within-group change</non_inferiority_desc>
            <p_value>0.0581</p_value>
            <p_value_desc>Follow-up vs End of treatment</p_value_desc>
            <method>Regression, Linear</method>
            <param_type>Least square mean</param_type>
            <param_value>-16.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.109</ci_lower_limit>
            <ci_upper_limit>0.664</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 24-hour Glucose Excretion From Baseline to Start of Treatment</title>
        <description>Average change in 24-hour glucose excretion from average baseline values to average start of treatment values (Day 2 to 4).</description>
        <time_frame>From baseline (Day -3 to Day -1) to start of treatment (Day 2 to 4)</time_frame>
        <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2</title>
            <description>Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
          <group group_id="O2">
            <title>Group 3</title>
            <description>Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 24-hour Glucose Excretion From Baseline to Start of Treatment</title>
          <description>Average change in 24-hour glucose excretion from average baseline values to average start of treatment values (Day 2 to 4).</description>
          <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.</population>
          <units>mmol/24 hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302.61" lower_limit="191.472" upper_limit="635.726"/>
                    <measurement group_id="O2" value="43.93" lower_limit="12.050" upper_limit="132.333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Within-group change</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Start of treatment vs baseline</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least square mean</param_type>
            <param_value>344.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>272.785</ci_lower_limit>
            <ci_upper_limit>416.905</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 24-hour Glucose Excretion From Baseline to End of Treatment</title>
        <description>Average change in 24-hour glucose excretion from average baseline values to average end of treatment values (Day 12 to 14)</description>
        <time_frame>From baseline (Day -3 to Day -1) to end of treatment (Day 12 to 14)</time_frame>
        <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2</title>
            <description>Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
          <group group_id="O2">
            <title>Group 3</title>
            <description>Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 24-hour Glucose Excretion From Baseline to End of Treatment</title>
          <description>Average change in 24-hour glucose excretion from average baseline values to average end of treatment values (Day 12 to 14)</description>
          <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.</population>
          <units>mmol/24 hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="283.40" lower_limit="155.876" upper_limit="762.801"/>
                    <measurement group_id="O2" value="29.88" lower_limit="15.450" upper_limit="113.300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Within-group change</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>End of treatment vs baseline</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least square mean</param_type>
            <param_value>311.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>224.528</ci_lower_limit>
            <ci_upper_limit>398.064</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 24-hour Glucose Excretion From End of Treatment to Follow-up</title>
        <description>Average change in 24-hour glucose excretion from average end of treatment values (Day 12 to 14) to average values during follow-up (Day 15 to 17).</description>
        <time_frame>From end of treatment (Day 12 to 14) to follow-up (Day 15 to 17)</time_frame>
        <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2</title>
            <description>Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
          <group group_id="O2">
            <title>Group 3</title>
            <description>Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 24-hour Glucose Excretion From End of Treatment to Follow-up</title>
          <description>Average change in 24-hour glucose excretion from average end of treatment values (Day 12 to 14) to average values during follow-up (Day 15 to 17).</description>
          <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.</population>
          <units>mmol/24 hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-168.43" lower_limit="-376.561" upper_limit="-107.596"/>
                    <measurement group_id="O2" value="-37.02" lower_limit="-74.733" upper_limit="-10.584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Within-group change</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Follow-up vs end of treatment</p_value_desc>
            <method>Regression, Linear</method>
            <param_type>Least square mean</param_type>
            <param_value>-203.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-235.983</ci_lower_limit>
            <ci_upper_limit>-170.162</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean 24-hour Systolic Blood Pressure From Baseline to Start of Treatment</title>
        <description>Change in mean 24-hour systolic blood pressure from baseline to start of treatment (Day 4)</description>
        <time_frame>From baseline (Day -1) to start of treatment (Day 4)</time_frame>
        <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2</title>
            <description>Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
          <group group_id="O2">
            <title>Group 3</title>
            <description>Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean 24-hour Systolic Blood Pressure From Baseline to Start of Treatment</title>
          <description>Change in mean 24-hour systolic blood pressure from baseline to start of treatment (Day 4)</description>
          <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.</population>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4810" lower_limit="-13.6610" upper_limit="5.6100"/>
                    <measurement group_id="O2" value="-8.9730" lower_limit="-24.6570" upper_limit="2.7210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Within-group change</non_inferiority_desc>
            <p_value>0.0047</p_value>
            <p_value_desc>Start of treatment vs baseline</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least square mean</param_type>
            <param_value>-5.2658</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.5459</ci_lower_limit>
            <ci_upper_limit>-1.9856</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean 24-hour Systolic Blood Pressure From Baseline to End of Treatment</title>
        <description>Change in mean 24-hour systolic blood pressure from baseline to end of treatment (Day 13).</description>
        <time_frame>From baseline (Day -1) to end of treatment (Day 13)</time_frame>
        <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2</title>
            <description>Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
          <group group_id="O2">
            <title>Group 3</title>
            <description>Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean 24-hour Systolic Blood Pressure From Baseline to End of Treatment</title>
          <description>Change in mean 24-hour systolic blood pressure from baseline to end of treatment (Day 13).</description>
          <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.</population>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9385" lower_limit="-16.0060" upper_limit="0.9160"/>
                    <measurement group_id="O2" value="-10.3290" lower_limit="-23.4160" upper_limit="16.2160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Within-group change</non_inferiority_desc>
            <p_value>0.0003</p_value>
            <p_value_desc>End of treatment vs baseline</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least square mean</param_type>
            <param_value>-7.0987</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.0379</ci_lower_limit>
            <ci_upper_limit>-4.1595</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean 24-hour Systolic Blood Pressure From End of Treatment to End of Follow-up</title>
        <description>Change in mean 24-hour systolic blood pressure from end of treatment (Day 13) to end of follow-up (Day 18).</description>
        <time_frame>From end of treatment (Day 13) to end of follow-up (Day 18)</time_frame>
        <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2</title>
            <description>Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
          <group group_id="O2">
            <title>Group 3</title>
            <description>Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean 24-hour Systolic Blood Pressure From End of Treatment to End of Follow-up</title>
          <description>Change in mean 24-hour systolic blood pressure from end of treatment (Day 13) to end of follow-up (Day 18).</description>
          <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.</population>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5140" lower_limit="-10.3420" upper_limit="8.4590"/>
                    <measurement group_id="O2" value="-2.6590" lower_limit="-16.3110" upper_limit="7.4680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Within-group change</non_inferiority_desc>
            <p_value>0.5592</p_value>
            <p_value_desc>Follow-up vs end of treatment</p_value_desc>
            <method>Regression, Linear</method>
            <param_type>Least square mean</param_type>
            <param_value>0.7287</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9894</ci_lower_limit>
            <ci_upper_limit>3.4468</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Volume From Baseline to Start of Treatment</title>
        <description>Change in plasma volume from baseline to start of treatment (Day 4).</description>
        <time_frame>From baseline (Day 1) to start of treatment (Day 4)</time_frame>
        <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2</title>
            <description>Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
          <group group_id="O2">
            <title>Group 3</title>
            <description>Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Volume From Baseline to Start of Treatment</title>
          <description>Change in plasma volume from baseline to start of treatment (Day 4).</description>
          <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.</population>
          <units>Litres</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1440" lower_limit="-1.7819" upper_limit="2.6385"/>
                    <measurement group_id="O2" value="-0.1139" lower_limit="-2.0340" upper_limit="0.0232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Within-group change</non_inferiority_desc>
            <p_value>0.9288</p_value>
            <p_value_desc>Start of treatment vs baseline</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least square mean</param_type>
            <param_value>0.0315</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7274</ci_lower_limit>
            <ci_upper_limit>0.7904</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Volume From Baseline to End of Treatment</title>
        <description>Change in plasma volume from baseline to end of treatment (Day 14).</description>
        <time_frame>From baseline (Day 1) to end of treatment (Day 14)</time_frame>
        <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2</title>
            <description>Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
          <group group_id="O2">
            <title>Group 3</title>
            <description>Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Volume From Baseline to End of Treatment</title>
          <description>Change in plasma volume from baseline to end of treatment (Day 14).</description>
          <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.</population>
          <units>Litres</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2122" lower_limit="-2.8346" upper_limit="1.1073"/>
                    <measurement group_id="O2" value="2.0557" lower_limit="2.0557" upper_limit="2.0557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Within-group change</non_inferiority_desc>
            <p_value>0.1659</p_value>
            <p_value_desc>End of treatment vs baseline</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least square mean</param_type>
            <param_value>-0.4318</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0761</ci_lower_limit>
            <ci_upper_limit>0.2125</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Plasma Volume From End of Treatment to End of Follow-up</title>
        <description>Change in plasma volume from end of treatment (Day 14) to end of follow-up (Day 18).</description>
        <time_frame>From end of treatment (Day 14) to end of follow-up (Day 18)</time_frame>
        <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2</title>
            <description>Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
          <group group_id="O2">
            <title>Group 3</title>
            <description>Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Volume From End of Treatment to End of Follow-up</title>
          <description>Change in plasma volume from end of treatment (Day 14) to end of follow-up (Day 18).</description>
          <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.</population>
          <units>Litres</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6464" lower_limit="-1.5016" upper_limit="1.6410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Within-group change</non_inferiority_desc>
            <p_value>0.0190</p_value>
            <p_value_desc>Follow-up vs end of treatment</p_value_desc>
            <method>Regression, Linear</method>
            <param_type>Least square mean</param_type>
            <param_value>0.4755</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0963</ci_lower_limit>
            <ci_upper_limit>0.8548</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Extracellular Volume From Baseline to Start of Treatment</title>
        <description>Change in extracellular volume from baseline to start of treatment (Day 4).</description>
        <time_frame>From baseline (Day 1) to start of treatment (Day 4)</time_frame>
        <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2</title>
            <description>Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
          <group group_id="O2">
            <title>Group 3</title>
            <description>Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Extracellular Volume From Baseline to Start of Treatment</title>
          <description>Change in extracellular volume from baseline to start of treatment (Day 4).</description>
          <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.</population>
          <units>Litres</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5783" lower_limit="-2.7027" upper_limit="0.7959"/>
                    <measurement group_id="O2" value="-0.4553" lower_limit="-1.3758" upper_limit="0.2282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Within-group change</non_inferiority_desc>
            <p_value>0.0157</p_value>
            <p_value_desc>Start of treatment vs baseline</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least square mean</param_type>
            <param_value>-0.6713</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1914</ci_lower_limit>
            <ci_upper_limit>-0.1511</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Extracellular Volume From Baseline to End of Treatment</title>
        <description>Change in extracellular volume from baseline to end of treatment (Day 14).</description>
        <time_frame>From baseline (Day 1) to end of treatment (Day 14)</time_frame>
        <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2</title>
            <description>Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
          <group group_id="O2">
            <title>Group 3</title>
            <description>Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Extracellular Volume From Baseline to End of Treatment</title>
          <description>Change in extracellular volume from baseline to end of treatment (Day 14).</description>
          <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.</population>
          <units>Litres</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1248" lower_limit="-1.4948" upper_limit="0.9852"/>
                    <measurement group_id="O2" value="-0.1427" lower_limit="-0.6101" upper_limit="1.0055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Within-group change</non_inferiority_desc>
            <p_value>0.8700</p_value>
            <p_value_desc>End of treatment vs baseline</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least square mean</param_type>
            <param_value>-0.0324</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4631</ci_lower_limit>
            <ci_upper_limit>0.3984</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Extracellular Volume From End of Treatment to End of Follow-up</title>
        <description>Change in extracellular volume from end of treatment (Day 14) to end of follow-up (Day 18).</description>
        <time_frame>From end of treatment (Day 14) to end of follow-up (Day 18)</time_frame>
        <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2</title>
            <description>Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
          <group group_id="O2">
            <title>Group 3</title>
            <description>Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Extracellular Volume From End of Treatment to End of Follow-up</title>
          <description>Change in extracellular volume from end of treatment (Day 14) to end of follow-up (Day 18).</description>
          <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented for Group 3.</population>
          <units>Litres</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1784" lower_limit="-0.6507" upper_limit="0.9780"/>
                    <measurement group_id="O2" value="0.1394" lower_limit="-0.3045" upper_limit="0.9014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Within-group change</non_inferiority_desc>
            <p_value>0.2446</p_value>
            <p_value_desc>Follow-up vs end of treatment</p_value_desc>
            <method>Regression, Linear</method>
            <param_type>Least square mean</param_type>
            <param_value>0.1718</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1358</ci_lower_limit>
            <ci_upper_limit>0.4795</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 24-hour Urine Albumin:Creatinine Ratio (UACR)</title>
        <description>Average change in mean 24-hour urine albumin:creatinine ratio (UACR) from average baseline to Day 4; and from average baseline values to average end of treatment values (Day 12 to 14).</description>
        <time_frame>From baseline (Day -3 to Day -1) to start of treatment (Day 4); and from baseline (Day -3 to Day-1) to end of treatment (Day 12 to 14)</time_frame>
        <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. It excluded primary efficacy variable data which may have been affected by protocol deviations as determined by medical monitor or agreed by study team. For Group 3, early termination of the study resulted in 6 evaluable patients. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2</title>
            <description>Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
          <group group_id="O2">
            <title>Group 3</title>
            <description>Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 24-hour Urine Albumin:Creatinine Ratio (UACR)</title>
          <description>Average change in mean 24-hour urine albumin:creatinine ratio (UACR) from average baseline to Day 4; and from average baseline values to average end of treatment values (Day 12 to 14).</description>
          <population>Evaluable patient set: all patients who dispensed at least one dose of study drug. It excluded primary efficacy variable data which may have been affected by protocol deviations as determined by medical monitor or agreed by study team. For Group 3, early termination of the study resulted in 6 evaluable patients. Due to insufficient number of patients recruited, no statistical conclusions were derived, and no confidence intervals or p-values are presented.</population>
          <units>mg/mmol</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Start of treatment vs baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" lower_limit="-30.750" upper_limit="6.700"/>
                    <measurement group_id="O2" value="-5.83" lower_limit="-35.300" upper_limit="0.300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment vs baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" lower_limit="-17.250" upper_limit="0.737"/>
                    <measurement group_id="O2" value="-7.28" lower_limit="-35.733" upper_limit="0.467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow-up vs end of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" lower_limit="-0.243" upper_limit="51.667"/>
                    <measurement group_id="O2" value="-0.19" lower_limit="-2.967" upper_limit="6.367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Within-group change</non_inferiority_desc>
            <p_value>0.0023</p_value>
            <p_value_desc>Start of treatment vs baseline</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least square mean</param_type>
            <param_value>-2.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.299</ci_lower_limit>
            <ci_upper_limit>-0.902</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Within-group change</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>End of treatment vs baseline</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least square mean</param_type>
            <param_value>-1.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.929</ci_lower_limit>
            <ci_upper_limit>-1.256</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Within-group change</non_inferiority_desc>
            <p_value>0.0002</p_value>
            <p_value_desc>Follow-up vs end of treatment</p_value_desc>
            <method>Regression, Linear</method>
            <param_type>Least square mean</param_type>
            <param_value>3.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.215</ci_lower_limit>
            <ci_upper_limit>5.553</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of Dapagliflozin on Day 4 and Day 14</title>
        <description>Dapagliflozin plasma concentration on Day 4 (pre-dose) and Day 14 (pre-dose, 1h, 2h, 4h post-dose)</description>
        <time_frame>At pre-dose (Day 4) and at pre-dose, 1h, 2h, 4h post-dose (Day 14)</time_frame>
        <population>Pharmacokinetic analysis set: all patients who were dispensed at least one dose of the study drug and for whom at least one of the plasma concentration samples were available and who had no important protocol deviations judged to impact the analysis of the PK data. Here, number analyzed in each row signifies only the patients with available data that were analyzed for that specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2</title>
            <description>Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
          <group group_id="O2">
            <title>Group 3</title>
            <description>Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Dapagliflozin on Day 4 and Day 14</title>
          <description>Dapagliflozin plasma concentration on Day 4 (pre-dose) and Day 14 (pre-dose, 1h, 2h, 4h post-dose)</description>
          <population>Pharmacokinetic analysis set: all patients who were dispensed at least one dose of the study drug and for whom at least one of the plasma concentration samples were available and who had no important protocol deviations judged to impact the analysis of the PK data. Here, number analyzed in each row signifies only the patients with available data that were analyzed for that specified time point.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 4, Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.58" spread="134.88"/>
                    <measurement group_id="O2" value="19.78" spread="116.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.54" spread="46.60"/>
                    <measurement group_id="O2" value="15.26" spread="41.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 1 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.46" spread="110.66"/>
                    <measurement group_id="O2" value="63.83" spread="150.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 2 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.47" spread="49.30"/>
                    <measurement group_id="O2" value="60.41" spread="140.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14, 4 h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.71" spread="47.38"/>
                    <measurement group_id="O2" value="47.83" spread="100.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With AEs and SAEs</title>
        <description>An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. SAE is an AE that results in any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, or is a significant medical event.</description>
        <time_frame>From Day 1 until Day 18 (Follow-up)</time_frame>
        <population>Safety set: all patients who received at least one dose of study drug and had data from at least one post-dose safety assessment available were included in the safety set.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2</title>
            <description>Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
          <group group_id="O2">
            <title>Group 3</title>
            <description>Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With AEs and SAEs</title>
          <description>An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. SAE is an AE that results in any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, or is a significant medical event.</description>
          <population>Safety set: all patients who received at least one dose of study drug and had data from at least one post-dose safety assessment available were included in the safety set.</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs judged as causally related to dapagliflozin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs (including outcomes = death)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs causally related to dapagliflozin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to permanent discontinuation of dapagliflozin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs leading to permanent discontinuation of dapagliflozin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycaemia AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycaemia AEs leading to permanent discontinuation of dapagliflozin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 until Day 18 (FU)</time_frame>
      <desc>SAEs and non-SAEs are reported for the Safety Set which comprised of all patients who received at least one dose of study drug and who had data from at least one post-dose safety assessment available.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 2</title>
          <description>Type 2 diabetes mellitus (T2DM) patients with preserved kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
        </group>
        <group group_id="E2">
          <title>Group 3</title>
          <description>Non-diabetic patients with impaired kidney function received oral dose of dapagliflozin 10 mg/day from Day 1 to Day 14, following which they entered Follow-up Period from Day 15 to Day 19.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA v22.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Genital infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Study results are Sponsor's intellectual property and PIs cannot present or publish results without prior Sponsor approval.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was prematurely closed due to unsatisfactory recruitment rate. Of 5 patients enrolled in the Group 1, none were enrolled into the Run-in set due to failure to meet inclusion/exclusion criteria, screen failure, withdrawal or other reason and hence it was decided that no more Group 1 patients would be enrolled in the study. In Group 2 and 3, 17 and 7 patients received the investigational product and completed the study, respectively.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Global Clinical Lead</name_or_title>
      <organization>AstraZeneca Clinical Study Information Center</organization>
      <phone>1-877-240-9479</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

